301258.SZ
Suzhou Fushilai Pharmaceutical Co., Ltd.
SZSE · C 制造业 · CN
CNY 26.06
−1.62%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 412.5M | 432.7M | 429.5M | 489.3M | 568.2M |
| Cost of Revenue | 343.3M | 360.5M | 345.2M | 301.4M | 311.2M |
| Gross Profit | 69.2M | 72.2M | 84.3M | 187.9M | 257.0M |
| Operating Expenses | |||||
| R&D Expense | 35.1M | 35.8M | 40.6M | 40.7M | 41.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 41.9M | 39.5M | 41.3M | 46.0M | 43.2M |
| Selling & Marketing Expense | 5.1M | 5.0M | 5.3M | 4.9M | 4.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 88.4M | 82.4M | 80.9M | 87.7M | 56.3M |
| Cost and Expenses | 431.7M | 443.0M | 426.1M | 389.1M | 367.4M |
| Operating Income (EBIT) | 45.4M | 76.6M | 20.2M | 133.6M | 205.7M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 43.6M | 74.8M | 18.2M | 128.5M | 202.5M |
| Income Tax Expense | 6.0M | 10.6M | 1.8M | 16.4M | 25.2M |
| Bottom Line | |||||
| Net Income | 37.6M | 64.3M | 16.4M | 112.2M | 177.3M |
| Earnings from Cont. Ops | 37.6M | 64.3M | 16.4M | 112.2M | 177.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 37.6M | 64.3M | 16.4M | 112.2M | 177.3M |
| Per Share | |||||
| Basic EPS | CN¥0.41 | CN¥0.71 | CN¥0.18 | CN¥1.22 | CN¥2.06 |
| Diluted EPS | CN¥0.41 | CN¥0.71 | CN¥0.18 | CN¥1.22 | CN¥2.06 |
| Revenue Per Share | CN¥4.65 | CN¥4.78 | CN¥4.71 | CN¥5.32 | CN¥6.60 |
| Shares | |||||
| Basic Shares Outstanding | 88.7M | 90.6M | 91.1M | 92.0M | 86.1M |
| Diluted Shares Outstanding | 88.7M | 90.6M | 91.1M | 92.0M | 86.1M |
| Profitability Metrics | |||||
| EBITDA | — | 125.3M | 69.9M | 190.4M | 257.3M |
| D&A | — | 48.6M | 49.7M | 56.7M | 51.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026